Enteromedics Inc (ETRM): Peter M. Delange , SVP, Ops & Bus Dev of Enteromedics Inc purchased 20,000 shares on Jun 3, 2016. The Insider buying transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.55 per share for a total value of $11,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Dan W Gladney (CEO) purchased 84,745 shares at $0.72 per share price.On Nov 16, 2015, Mark B Knudson (CEO) purchased 310,000 shares at $0.16 per share price.
EnteroMedics Inc: On Friday, Jun 3, 2016 heightened volatility was witnessed in EnteroMedics Inc which led to swings in the share price. The shares opened for trading at $0.5 and hit $0.5499 on the upside , eventually ending the session at $0.51, with a gain of 2.51% or 0.0125 points. The heightened volatility saw the trading volume jump to 97,827 shares. The 52-week high of the share price is $18.299908 and the company has a market cap of $4.7 M . The 52-week low of the share price is at $0.4504.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology which is referred to as VBLOC therapy is designed to intermittently block the vagus nerve using high frequency low energy electrical impulses. The Company’s initial product is the Maestro System which uses VBLOC therapy to affect metabolic regulatory control limits the expansion of the stomach help control hunger sensations between meals reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product the Maestro Rechargeable System in the United States Australia the European Economic Area and other countries.